COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Radiofrequency Ablation in Treating Patients Who Are Undergoing Surgery for Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00103155
Recruitment Status : Unknown
Verified August 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : February 8, 2005
Last Update Posted : September 20, 2013
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Ultrasound-guided radiofrequency ablation may be effective treatment for thyroid cancer.

PURPOSE: This phase I trial is studying the side effects of radiofrequency ablation in treating patients who are undergoing surgery for thyroid cancer.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Procedure: conventional surgery Procedure: radiofrequency ablation Phase 1

Detailed Description:


  • Determine the frequency of complications associated with radiofrequency ablation (RFA) in patients with low-risk papillary thyroid cancer undergoing thyroidectomy.
  • Determine the utility of RFA as a treatment option for these patients.

OUTLINE: This is a pilot study.

An electrosurgical probe is placed by ultrasound guidance into the center of the thyroid tumor. Patients undergo radiofrequency ablation directly to the tumor until the target temperature is reached* for 5 minutes. Patients then undergo standard thyroidectomy.

NOTE: *Takes approximately 15-30 minutes to reach target temperature.

After completion of study treatment, patients are followed at day 1, between days 14-21, and then periodically as deemed necessary.

PROJECTED ACCRUAL: A total of 15-40 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Radiofrequency Ablation for Low Risk Papillary Thyroid Cancer: A Pilot Study
Study Start Date : September 2004

Resource links provided by the National Library of Medicine

Drug Information available for: Thyroid

Primary Outcome Measures :
  1. Frequency of radiofrequency ablation-associated complications at 2 weeks

Secondary Outcome Measures :
  1. Amount of tumor destruction at 2 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Cytologically confirmed papillary thyroid cancer by fine needle aspiration

    • Low-risk disease
    • No poorly differentiated cytology
  • Intrathyroidal tumor

    • Located within the anterior two-thirds of the thyroid lobe
    • Tumor not adjacent to the trachea by neck ultrasound
  • Tumor ≤ 1.5 cm by neck ultrasound
  • Requires thyroidectomy
  • No cervical lymphadenopathy
  • No multicentric tumors by neck ultrasound
  • No evidence of lymph node metastasis



  • Over 21

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


Biologic therapy

  • Not specified


  • Not specified

Endocrine therapy

  • Not specified


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00103155

Layout table for location information
United States, California
UCSF Comprehensive Cancer Center
San Francisco, California, United States, 94143-1674
Sponsors and Collaborators
University of California, San Francisco
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Electron Kebebew, MD University of California, San Francisco

Layout table for additonal information Identifier: NCT00103155    
Other Study ID Numbers: CDR0000410790
First Posted: February 8, 2005    Key Record Dates
Last Update Posted: September 20, 2013
Last Verified: August 2005
Keywords provided by National Cancer Institute (NCI):
stage I papillary thyroid cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms